Work

1960P Subcutaneous (SC) amivantamab (ami) plus chemotherapy (chemo) in EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC) after disease progression on osimertinib (osi)

Year: 2025

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.2584

Authors: E. Nadal, J. Neal, D. Signorelli, J.L. Tan, V.C. Cordeiro de Lima, K-J. Tang, S. Benafif, M.T. Moskovitz, A. Ono, M. Reck, S. hiret, S.N. Waqar, S. DAS, A. Alhadab, M. Wang, J. Mahoney, J. Zhang, S. Shah, M. Baig, S.M. Lim

Institutions: Institut Català d'Oncologia, Stanford Medicine, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University Malaya Medical Centre, University of Malaya, AC Camargo Hospital, The First Affiliated Hospital, Sun Yat-sen University, University College London Hospitals NHS Foundation Trust, Shizuoka Cancer Center, German Center for Lung Research, LungenClinic Grosshansdorf, Institut de Cancérologie de l'Ouest, Washington University in St. Louis, Johnson & Johnson (India), Johnson & Johnson (United States), Yonsei University, Yonsei University Health System

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Johnson and Johnson

OpenAlex ID: W4415941489

FWCI:

Cites:

Cited by:

Related to: 10